NBIX
Neurocrine Biosciences, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +17.3% · netto nieuwe posities 0.0% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 5 | -1 | 774.42K | $108.76M | n/a | −1 |
| Q2 2026 | 154 | 0 | 76.05M | $12.81B | +5 | −4 |
| Q1 2026 | 156 | 0 | 77.10M | $10.14B | +6 | −7 |
| Q4 2025 | 155 | 0 | 77.25M | $10.95B | +1 | n/a |
| Q3 2025 | 22 | 0 | 59.57M | $8.36B | +1 | −2 |
| Q2 2025 | 20 | -1 | 49.44M | $6.21B | +2 | −3 |
| Q1 2025 | 18 | 0 | 22.97M | $2.54B | +1 | −1 |
| Q4 2024 | 18 | 0 | 21.48M | $2.93B | +1 | −1 |
| Q3 2024 | 17 | 0 | 13.43M | $1.55B | n/a | n/a |
| Q2 2024 | 17 | n/a | 11.91M | $1.64B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passief) | 4.89M | n/a | $667.65M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Dodge & Cox ✦ | 3.02M | +134.2% | $411.74M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 2.54M | +43.8% | $346.45M | 0.3% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Renaissance Technologies ✦ | 2.49M | -3.3% | $339.80M | 0.5% | ▼ Trim | 3 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 1.90M | +2.9% | $258.93M | 0.3% | ▲ Add | 3 | SEC ↗ ×6 |
| 6 | Geode Capital Management ✦ (passief) | 1.88M | +0.8% | $255.52M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | T. Rowe Price ✦ | 1.49M | -11.0% | $203.46M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 1.46M | +102.9% | $198.94M | 0.0% | ▲ Add | 3 | SEC ↗ ×6 |
| 9 | Millennium Management ✦ | 418.71K | +33.9% | $57.15M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 10 | PRIMECAP Management ✦ | 393.71K | -2.5% | $53.74M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Bridgewater Associates ✦ | 332.60K | +146.0% | $45.40M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 12 | Norges Bank ✦ (passief) | 325.30K | -7.3% | $44.40M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | Soros Fund Management ✦ | 200.00K | +33.3% | $27.30M | 0.7% | ▲ Add | 3 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 92.10K | +34.9% | $12.57M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 28.71K | -83.1% | $3.92M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 26.77K | -70.3% | $3.65M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 5.71K | -62.7% | $779,961 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Marshall Wace ✦ | 2.42K | Nieuw | $331,013 | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Marshall Wace | $331,013 | 0.0% |
Verlaten
| Arrowstreet Capital | $996,768 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 690 houders, 94.09M aandelen, $12.08B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 826 aand · $130,051
Officer · 2.31K aand · $363,285
Officer · 2.15K aand · $333,030
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie